R&D Pipeline

Phase:

Therapy:

Pipeline last updated 30 January 2014
Compound/indication Phase 1 Phase 2 Phase 3 Filed
Tresiba® (insulin degludec) (NN1250)

Type 1 and 2 diabetes
Ryzodeg® (insulin degludec and insulin aspart) (NN5401)

Type 1 and 2 diabetes
IDegLira (NN9068)

Type 2 diabetes
Liraglutide 3 mg (NN8022)

Obesity
Faster-acting insulin aspart (NN1218)

Type 1 and 2 diabetes
Semaglutide (NN9535)

Type 2 diabetes
LATIN T1D (NN9211)

Type 1 diabetes
N8-GP (NN7088)

Haemophilia A
N9-GP (NN7999)

Haemophilia B
OG217SC (NN9924)

Type 2 diabetes
Anti-IL20 (NN8226)

Inflammation - Rheumatoid arthritis
Anti-IL21 (NN8828)

Inflammation - Crohn's disease
Anti-NKG2D (NN8555)

Inflammation - Crohn's disease
LAI287 (NN1436)

Type 1 and 2 diabetes
OG987GT (NN9926)

Type 2 diabetes
OG987SC (NN9927)

Type 2 diabetes
OG217GT (NN9928)

Type 2 diabetes
OI338GT (NN1953)

Type 1 and 2 diabetes
OI362GT (NN1954)

Type 1 and 2 diabetes
OI287GT (NN1956)

Type 1 and 2 diabetes
Concizumab (mAb2021)

Haemophilia A and B
NN8640

Growth disorder
Anti-IL21 (NN8828)

Inflammation - Systemic lupus erythematosus
Anti-C5aR-215 (NN8210)

Inflammation - Rheumatoid arthritis
Anti-NKG2A (NN8765)

Inflammation - Rheumatoid arthritis
  •